Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
Latvija -
latviešu -
Zāļu valsts aģentūra
clormetin 2 mg/0,03 mg apvalkotās tabletes
exeltis baltics uab, lithuania - chlormadinoni acetas, ethinylestradiolum - apvalkotā tablete - 2 mg/0,03 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
lokren 20 mg apvalkotās tabletes
sanofi-aventis france, france - betaksolola hidrohlorīds - apvalkotās tabletes - 20 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
betahistine accord 24 mg tabletes
accord healthcare b.v., netherlands - betahistīna dihidrohlorīds - tablete - 24 mg